Get the Stockscreener App
5.10
1.54%
-0.08
Cingulate Inc stock is traded at $5.10, with a volume of 64,133.
It is down -1.54% in the last 24 hours and up +23.19% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$5.18
Open:
$5.08
24h Volume:
64,133
Relative Volume:
0.42
Market Cap:
$26.25M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1564
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
-7.27%
1M Performance:
+23.19%
6M Performance:
+12.09%
1Y Performance:
+25.74%
1-Day Range:
$4.80
$5.14
1-Week Range:
$4.80
$5.5348
52-Week Range:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
5.10 | 26.66M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
What makes Cingulate Inc. stock price move sharplyPost Market Opportunities With High Returns - jammulinksnews.com
Is Now a Good Time to Reenter Cingulate Inc.Low Risk Picks for Daily Trading Released - metal.it
What is Cingulate Inc. Equity Warrant company’s growth strategyFree Stock Updates For 2025 - jammulinksnews.com
What is the dividend policy of Cingulate Inc. stockExpert Picks Guidance For 2025 - jammulinksnews.com
How many analysts rate Cingulate Inc. as a “Buy”Beginner Investor Data Feed With High Returns - jammulinksnews.com
What are analysts’ price targets for Cingulate Inc. in the next 12 monthsBreakout Stocks Tips That Work - jammulinksnews.com
What markets is VERB expanding into Is Cingulate Inc. stock a good long term investment optionStock Strategy Entry Points Backed By Experts - jammulinksnews.com
What catalysts could drive Cingulate Inc. stock higher in 2025Financial News Target Finder For Smart Trading - jammulinksnews.com
Cingulate gets $4.3M waiver, clearing way to submit for FDA approval - The Business Journals
How volatile is Cingulate Inc. stock compared to the marketFinancial News Tips To Watch Now - jammulinksnews.com
Cingulate Inc. Receives Buy Rating: PDUFA Fee Waiver and Competitive Edge of CTx-1301 Boost Market Prospects - TipRanks
Risk adjusted return profile for Cingulate Inc. analyzedMarket Correction Proof Stock Screening Analysis - Newser
Applying chart zones and confluence areas to Cingulate Inc. Equity WarrantFree Value Investing Picks With Stability - Newser
Visual trend scoring systems applied to Cingulate Inc. Equity WarrantFundamental + Technical Combined Watchlist - Newser
Will Cingulate Inc. Equity Warrant benefit from macro trendsPredictable Income Summary for Long-Term Trades - Newser
Evaluating Cingulate Inc. with trendline analysisDaily Market Entry Strategy with Tools - Newser
Cingulate Inc. stock outlook for YEARFundamental + Technical Combined Watchlist - Newser
Why Cingulate Inc. stock attracts strong analyst attentionEntry Alert With Low Drawdown Strategy Noted - metal.it
Cingulate Inc. Equity Warrant Recovery Linked to Earnings SurpriseReal Trader Watchlist of Hot Stocks Released - metal.it
What risks could impact Cingulate Inc. Equity Warrant stock performanceAI Entry Timing Prediction for Swing Traders - Newser
How Cingulate Inc. stock performs during market volatilityFree Real Time Alerts Based on AI Prediction - Newser
Cingulate Inc. Shows Support at Fibonacci LevelBuy Alerts With Low Risk Confirmation Noted - metal.it
Quant Tools Rank Cingulate Inc. Equity Warrant as High Risk High RewardVerified Signal From Chart Patterns Detected - beatles.ru
How high can Cingulate Inc. stock goHigh Return Strategy with Low Risk - Newser
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent - GlobeNewswire
Analysts Apply Wyckoff Model to Cingulate Inc. Equity Warrant StockConsistent Gain Investment Strategies Emerge - metal.it
Cingulate Receives $4.3 Million PDUFA Fee Waiver for ADHD Treatment, CTx-1301 - Psychiatric Times
Cingulate receives $4.3M waiver from FDA for NDA for CTx-1301 - TipRanks
Cingulate's PDUFA Fee Waiver and CTx-1301: A Strategic Catalyst for Value Creation in ADHD Therapeutics - AInvest
Cingulate receives FDA fee waiver for ADHD drug application By Investing.com - Investing.com India
Cingulate Saves $4.3M on ADHD Drug Application as FDA Waiver Boosts Commercialization Plans - Stock Titan
Why Cingulate Inc. Equity Warrant stock attracts strong analyst attentionDaily Trade Monitor with Pattern Alerts - Newser
Is Cingulate Inc. Stock Overbought or Oversold RSI Indicator AnalysisDaily Market Momentum and Pressure Analysis - Newser
Can Cingulate Inc. Equity Warrant Escape Recent Bear ChannelExit Ready Momentum Stock Watchlist Expanded - metal.it
What makes Cingulate Inc. Equity Warrant stock price move sharplyEarnings Report Planner For 2025 - jammulinksnews.com
How does Cingulate Inc. Equity Warrant generate profit in a changing economyChart Pattern Growth Plan For Smart Trading - jammulinksnews.com
Can technical indicators confirm Cingulate Inc.’s reversalFree Daily Profit Focused Stock Screener - Newser
Will Cingulate Inc. price bounce be sustainableCapital Safe Picks with Consistent Gains - Newser
What technical models suggest about Cingulate Inc.’s comeback Low Drawdown Picks with Weekly Updates - Newser
Cingulate Inc. Stock Performance After Earnings: Historical Insights Annual Market Behavior and Sector Summary - Newser
What is the risk reward ratio of investing in Cingulate Inc. stockCapitalize on trading strategies that deliver - jammulinksnews.com
Is it the right time to buy Cingulate Inc. stockExponential return rates - jammulinksnews.com
Does Cingulate Inc. Equity Warrant stock perform well during market downturnsBuild wealth faster with high-performing stocks - jammulinksnews.com
How many analysts rate Cingulate Inc. Equity Warrant as a “Buy”Get exclusive access to premium stock research - jammulinksnews.com
What is Cingulate Inc. company’s growth strategyDiscover high-growth stocks for your portfolio - jammulinksnews.com
How does Cingulate Inc. Equity Warrant compare to its industry peersFree Stock Chart Pattern Guide - jammulinksnews.com
What institutional investors are buying Cingulate Inc. Equity Warrant stockInvest smarter with cutting-edge analytics - jammulinksnews.com
What catalysts could drive Cingulate Inc. Equity Warrant stock higher in 2025Triple-digit return opportunities - jammulinksnews.com
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):